DEF: Elite Health Systems Seeks Approval for Acquisition, Stock Plan

Elite Health Systems seeks stockholder approval for a special meeting to vote on key proposals including a share increase, equity incentive plan, and acquisition of Physician Support Systems, Inc.

Summary

• Elite Health Systems Inc. (EHSI) is holding a special meeting of stockholders on October 31, 2025, to vote on several key proposals.
• Proposal 1: Elect five directors to the Board of Directors for a one-year term.
• Proposal 2: Amend the company's Certificate of Incorporation to increase the authorized shares of common stock from 25,000,000 to 50,000,000.
• Proposal 3: Approve the 2025 Equity Incentive Plan with 4,500,000 shares of common stock subject to the plan.
• Proposal 4: Approve the acquisition of Physician Support Systems, Inc. (PSS) by issuing 3,158,000 shares of EHSI common stock.
• Proposal 5: Ratify the appointment of Mercurius & Associates LLP as independent auditors for the fiscal year ending December 31, 2025.
• Proposal 6: Approve possible adjournment of the meeting to solicit additional proxies.
• The Board of Directors recommends voting FOR all proposals.

Sentiment

Score: 4

Explanation: The filing contains both positive and negative aspects. The acquisition of PSS is expected to strengthen the company, but there are also risks associated with the acquisition and the need to raise additional capital.

Positives

• The acquisition of PSS is expected to strengthen EHSI's health experience, access to providers, and management team.
• PSS is an operating business with revenue and positive net earnings, which is expected to strengthen EHSI's financial statements.
• The Board believes the combined enterprise will have greater access to capital and recognition by the public markets.
• The Board believes a stronger financial and operating company will likely be viewed positively by State and Federal regulators and the commercial insurance and healthcare markets.
• The proposed increase in authorized shares will provide the company with greater flexibility for future financings, acquisitions, and strategic business expansion opportunities.
• The 2025 Equity Incentive Plan is intended to attract, motivate, reward, and retain employees, consultants, and directors.

Negatives

• If the Authorized Shares Increase Proposal is not approved, the company will be unable to raise the full amount proposed to be issued in connection with its ongoing private placement of up to $5 million and will not be able to complete the share issuance in connection with the Acquisition Agreement.
• If the Acquisition is not consummated, Elite will not complete the share issuance pursuant to the Acquisition Agreement and Elite will continue to operate without owning the assets and businesses of PSS.
• The issuance of shares of the Company’s common stock to the stockholders of PSS in the Acquisition will substantially dilute the voting power of current stockholders of the Company.
• The number of the Company’s common stock issued as consideration for the Acquisition is not adjustable based on the applicable market price at the time of the issuance so the Acquisition consideration at the closing may have a greater value than at the time the Acquisition Agreement was signed.
• Because PSS is a private company, it is difficult to evaluate the value of the combined companies, and the agreed upon consideration the Selling Stockholders will receive for the Acquisition may be greater than the value of the businesses of PSS.
• The Company is subject to various uncertainties and contractual restrictions, including the risk of litigation, while the Merger is pending, which may cause disruption and may make it more difficult to maintain relationships with employees and third parties.
• The Company may not know all material issues of PSS from due diligence and subsequent to the consummation of the Acquisition, the Company may be required to take actions, restructuring and impairment or other charges that could have a significant negative effect on its financial condition, results of operations and stock price, which could cause you to lose some or all of your investment.
• Some executive officers and directors have interests in the Acquisition that are different from your interests and such differing interests of such officers and directors may influence them to support or approve the Acquisition without regard to your interests.
• The concentration of capital stock ownership with Dr. Jeereddi and his affiliates and related person after the Acquisition may limit the ability of other stockholders of the Company to influence corporate matters.
• The health care industry is heavily regulated. The Company’s and/or PSS failure to comply with regulatory requirements could create liability for it, result in adverse publicity and otherwise negatively affect its business.

Risks

• The occurrence of any event, change or other circumstances that could give rise to the termination of the Acquisition Agreement.
• The inability to complete the Acquisition due to the failure to obtain stockholder approval or any third party, governmental or regulatory clearances or the failure to satisfy other conditions to the closing of the Acquisition or for any other reason.
• Legal or regulatory proceedings or other matters that affect the timing or ability to complete the Acquisition as contemplated.
• The risk that the proposed Acquisition disrupts current plans and operations.
• Fluctuations in the market value of the Company's common stock.
• The effects of the Acquisition on the financial results of the Company and PSS.
• Disruption from the Acquisition making it difficult to maintain business and operational relationships.
• Diversion of management time on issues related to the Acquisition.
• The risk that the businesses will not be integrated successfully, or that the integration will be more costly or more time consuming and complex than anticipated.
• The risk that synergies anticipated to be realized from the Acquisition may not be fully realized or may take longer to realize than expected.
• Adverse developments in general market, business, economic, labor, regulatory and political conditions.
• The amount of any costs, fees, expenses, impairments and charges related to the Acquisition.
• Uncertainty regarding the adequacy of the Company's and PSSs liquidity to pursue its respective business objectives.
• The impact of any outbreak or escalation of hostilities on a national, regional or international basis, acts of terrorism or natural disasters.
• The impact of any change to applicable laws and regulations affecting domestic and foreign operations, including those relating to trade, monetary and fiscal policies, taxes, price controls, regulatory approval of new products, licensing, and healthcare reform.
• The issuance of shares of the Company's common stock to the stockholders of PSS in the Acquisition will substantially dilute the voting power of current stockholders of the Company.
• The number of the Company's common stock issued as consideration for the Acquisition is not adjustable based on the applicable market price at the time of the issuance so the Acquisition consideration at the closing may have a greater value than at the time the Acquisition Agreement was signed.
• Because PSS is a private company, it is difficult to evaluate the value of the combined companies, and the agreed upon consideration the Selling Stockholders will receive for the Acquisition may be greater than the value of the businesses of PSS.
• If the Company and PSS are not successful in integrating their businesses and organizations, the anticipated benefits of the Acquisition may not be realized.
• The Company is subject to various uncertainties and contractual restrictions, including the risk of litigation, while the Merger is pending, which may cause disruption and may make it more difficult to maintain relationships with employees and third parties.
• The Company may not know all material issues of PSS from due diligence and subsequent to the consummation of the Acquisition, the Company may be required to take actions, restructuring and impairment or other charges that could have a significant negative effect on its financial condition, results of operations and stock price, which could cause you to lose some or all of your investment.
• Some executive officers and directors have interests in the Acquisition that are different from your interests and such differing interests of such officers and directors may influence them to support or approve the Acquisition without regard to your interests.
• The concentration of capital stock ownership with Dr. Jeereddi and his affiliates and related person after the Acquisition may limit the ability of other stockholders of the Company to influence corporate matters.
• The health care industry is heavily regulated. The Company's and/or PSS failure to comply with regulatory requirements could create liability for it, result in adverse publicity and otherwise negatively affect its business.

Future Outlook

The company anticipates that the Acquisition will close within several days after the Meeting to be held on October 14, 2025, but the Company cannot predict the exact timing. The proposal to increase the aggregate number of shares we are authorized to issue will provide us the ability to raise additional capital such as the private placement we are currently pursuing and will allow us to make acquisitions or pursue other strategic business expansion opportunities.

Management Comments

• "The proposal to increase the aggregate number of shares we are authorized to issue will provide us the ability to raise additional capital such as the private placement we are currently pursuing and will allow us to make acquisitions or pursue other strategic business expansion opportunities."
• "The Company believes that the capabilities of PSS will be helpful in establishing and in furtherance of processes, procedures and related corporate infrastructure that would be necessary to support Medicare Advantage plans."
• "The Company further believes PSS will provide it with access to health services that will enable the Company to efficiently support those plans."

Industry Context

The healthcare industry is heavily regulated and is constantly evolving due to the changing political, legislative, and regulatory landscape and other factors. Many health care laws are complex, and their application to specific services and relationships may not be clear. Further, some health care laws differ from state to state, and it is difficult to ensure PSSs business complies with the evolving laws applicable.

Comparison to Industry Standards

• The filing does not contain any specific comparisons to industry standards or benchmarks.
• The filing does not contain any specific comparisons to comparable companies.
• The filing does not contain any specific comparisons to comparable projects.
• The filing does not contain any specific comparisons to comparable results.

Corporate Governance

Related Party Transactions

• The company has been in discussion with, and proposed to move forward with, PSS regarding a prospective stock exchange transaction, pursuant to which the company will be issuing 3,158,000 shares of the company's common stock to the current shareholders of PSS in exchange for all current issued and outstanding capital stock of PSS.
• The prospective PSS transaction is a related party transaction as defined in Item 404(a) of Regulation S-K as Dr. Jeereddi serves as the CEO of the company and, collectively with his immediate family member, owns 90% of the outstanding capital stock of PSS.
• Dr. Jeereddis immediate family member also serves as the executive officer of PSS and is participating in the negotiation of the prospective PSS transaction.

Stakeholder Impact

• Shareholders: Dilution of ownership and voting power due to the issuance of new shares for the acquisition of PSS. Potential benefits from the acquisition if it strengthens the company's operations and financial performance.
• Employees: Potential changes in roles and responsibilities due to the integration of PSS. Opportunity for growth and development if the combined company is successful.
• Customers: Potential for improved services and offerings if the acquisition strengthens the company's capabilities.
• Suppliers: Potential changes in relationships and contracts due to the integration of PSS.
• Creditors: Potential impact on the company's financial stability and creditworthiness due to the acquisition and the need to raise additional capital.

Next Steps

• Stockholders to vote on the proposals at the Special Meeting on October 31, 2025.
• If approved, the company will proceed with the acquisition of PSS and the implementation of the 2025 Equity Incentive Plan.
• The company will continue to pursue its private placement of shares of common stock.

Key Dates

Recommendation

The filing presents a mixed picture. While the acquisition of PSS could strengthen the company, there are also significant risks and potential conflicts of interest. The need to raise additional capital and the potential dilution of existing shareholders are also concerns. A hold recommendation is appropriate until there is more clarity on the success of the acquisition and the company's ability to execute its strategy.

Keywords

Acquisition, Proxy Statement, Stockholder Meeting, Equity Incentive Plan, Physician Support Systems, Merger, Elite Health Systems, Corporate Governance, Healthcare